Kyowa Kirin Goes Global With MEI’s PI3K Contender In $683m Deal
Japanese firm builds on existing alliance to gain most global rights to US company’s potential best-in-class drug for lymphoma and B-cell malignancies.
Japanese firm builds on existing alliance to gain most global rights to US company’s potential best-in-class drug for lymphoma and B-cell malignancies.